Sun Pharmaceutical

Sun Pharmaceutical Q1 FY25 Results: India formulation sales grew by 16.4 percent to Rs 4,144 crore, accounting for about 33.1 percent of total consolidated sales.

Sun Pharma shares decline on report of four observations from US FDA

The US FDA inspected Sun Pharma's Dahej and issued four observations along with form-483, as per reports.

NPPA makes 33 fixed-dose combination drugs cheaper, brings them under regulation

The 33 drugs includes two each from JB Chemicals and Pharmaceuticals, Eris Lifesciences, Zydus Healthcare, Cipla, Sun Pharmaceutical, and Sanofi India and one from Torrent Pharma.

Sun Pharma recalls over 34k bottles of generic drug in US due to manufacturing issues

As per the US Food and Drug Administration's Enforcement Report, the US-based arm of Sun Pharmaceutical Industries is recalling lots of Diltiazem Hydrochloride extended-release capsules which are used to treat angina, high blood pressure and some types of irregular heartbeats.

Sun Pharmaceutical recalls over 10,000 bottles of generic anti-depression drug in US

10,500 bottles of a generic medication used to treat serious depression are being recalled by drug producer Sun Pharma after customer complaints.

Aurobindo, Sun Pharma recall products in US market

The USFDA stated that Aurobindo Pharma USA Inc, a unit of Hyderabad-based drug major, is recalling 4,33,809 vials of Cyanocobalamin injection for being a "Subpotent Drug".

Buy Sun Pharmaceutical; target of Rs 786: Dolat Capital Market

Dolat Capital Market is bullish on Sun Pharmaceutical has recommended buy rating on the stock with a target price of Rs 786 in its research report dated May 28, 2021.

Lupin, Sun Pharma recall drugs in the US market

The Mumbai-based drug maker Lupin is recalling 11,688 bottles of Lisinopril tablets USP, 10 mg, which is used to treat high blood pressure, in the US market, as per the latest Enforcement Report by the US health regulator.

Sun Pharma board to consider share buyback plan next week

It added that in this connection, as per the company's code of conduct for prevention of insider trading, the trading window for dealing or trading in securities will remain closed with immediate effect for all directors, designated persons and insiders.

Sun Pharma launches severe nodular acne management capsules in US

The product launched by company's wholly owned subsidiaries for the management of severe recalcitrant nodular acne in patients of 12 years of age and older, it can be taken with or without food, Sun Pharma said in a filing to BSE.

Sun Pharma inks global licensing pact with CSIR-IICT for patents

The pact is for patents related to certain compounds with potential therapeutic activity across multiple indications.

Sun Pharmaceutical launched cancer drug in US market

In July 2018, Sun Pharma had received approval from the US health regulator for INFUGEM injection.

Sun Pharma recalls about 14k cartons of anaesthesia injection from US market

"Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd. is voluntarily recalling three lots of Vecuronium Bromide for Injection, 10 mg (lyophilized powder), and one lot of Vecuronium Bromide for Injection, 20 mg (lyophilized powder) to the hospital level.

Glenmark gets USFDA nod for skin ointment

Glenmark said it is eligible for 180 days of competitive generic therapy (CGT) exclusivity upon commercialisation.

A morning walk down Dalal Street | Nifty to find support around 10,750, stay cautious while picking stocks

There is some caution ahead of the outcome of the RBI's monetary policy review meet which triggered profit-taking as the session progressed, suggest experts.

Market Headstart: Nifty likely to open above 10,900; 3 stocks that could return 3-5%

Trends on SGX Nifty indicate a flat-to-positive opening for the index in India, at around 8 points or 0.07 percent higher

Podcast | Stock Picks of the Day: Nifty may face resistance around 10,950; 3 trading ideas for Dec series

Dinesh Rohira of 5nance.com advises traders to remain selective and use the rally to book profit

A morning walk down Dalal Street | Market likely to remain volatile ahead of MPC meet outcome with support at 10,650

Most experts feel that this week is likely to remain volatile ahead of MPC meet outcome and outcome of state elections which is due next week.

Sun Pharma gets Australia TGA nod for plaque psoriasis treatment drug

"We are pleased to have received this approval and look forward to bringing ILUMYA to dermatologists and patients in Australia," Sun Pharma Business Head, Western Europe and Australia, Hellen De Kloet said in a statement.

Sun Pharmaceutical signs Virat Kohli as brand ambassador for Volini

A marketing campaign featuring Virat Kohli goes live today, the company said.

Accumulate Sun Pharmaceutical; target of Rs 539: KRChoksey

KRChoksey recommended accumulate rating on Sun Pharmaceutical with a target price of Rs 539 in its research report dated May 29, 2018.

Sun Pharma recalls over 17.5 K bottles of nasal spray from US

As per the enforcement report for week of February 21, 2017 of the US FDA, Sun Pharmaceutical Industries Inc is recalling 17,554 bottles of Azelastine HCl Nasal Solution (Nasal Spray) 0.1 per cent (137 mcg per spray), 30 ml.

Sun Pharmaceutical – is the dawn near?

The management maintained its earlier guidance of single-digit revenue decline in FY2018 and EBITDA margin performance of 20-22% in the second half.

Prefer Dr Reddy's, Sun Pharmaceutical: Hemant Thukral

Hemant Thukral of Aditya Birla Money is of the view that one may prefer Dr Roddy’s Laboratories and Sun Pharmaceutical.

Buy Bharat Forge, Colgate, Federal Bank; sell Sun Pharma: Ashwani Gujral

Ashwani Gujral of ashwanigujral.com advises buying Bharat Forge, Colgate Palmolive, Federal Bank and India Cements.